Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin in HER2-Expressing Solid Tumors
NCT06003231Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Nov 2023
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 7
01
Overview
A Phase 2 trial of disitamab vedotin in head and neck cancer (HNC), non-small cell lung cancer (NSCLC), ovarian cancer, endometrial cancer (EC), sponsored by Pfizer. Started Nov 2023; status: active, not recruiting.
02
Drugs
disitamab vedotin
03
Conditions
head and neck cancer (HNC)non-small cell lung cancer (NSCLC)ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT06003231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06003231.